IM156

DRUG2 trials

Sponsors

ImmunoMet Therapeutics, Inc., M.D. Anderson Cancer Center

Conditions

Advanced Solid TumorPancreas Cancer

Phase 1

Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma

CompletedNCT03272256

ImmunoMet Therapeutics, Inc.Advanced Solid Tumor

Start: 2017-10-09End: 2020-07-28Updated: 2020-10-19

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

Active, not recruitingNCT05497778

M.D. Anderson Cancer CenterPancreas Cancer

Start: 2022-10-21End: 2027-02-02Target: 19Updated: 2026-06-24

Related Papers

A phase 1b dose escalation trial of gemcitabine and nab-paclitaxel in combination with lixumistat in patients with advanced pancreatic cancer.

Journal of Clinical Oncology2025-01-272 citations

IM156 Attenuates Mitochondrial Reprogramming and Inhibits Pulmonary Fibrosis

2021-05-01

Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.

Journal of Clinical Oncology2020-05-2016 citations

Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors

Cancer Research2019-07-012 citations

Abstract CT021: Phase I study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors

Clinical Trials2019-07-011 citations

Phase 1 study of an oxidative phosphorylation inhibitor IM156 in patients with advanced solid tumors.

Journal of Clinical Oncology2018-05-201 citations